Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated Central Line-Associated Bloodstream Infections from Oncology Settings, 2009–2012
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

For very narrow results

When looking for a specific result

Best used for discovery & interchangable words

Recommended to be used in conjunction with other fields

Dates

to

Document Data
Library
People
Clear All
Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Causative Organisms and Associated Antimicrobial Resistance in Healthcare-Associated Central Line-Associated Bloodstream Infections from Oncology Settings, 2009–2012

Filetype[PDF-187.60 KB]


English
Details Supporting Files You May Also Like

Details:

  • Alternative Title:
    Clin Infect Dis
  • Personal Author:
  • Description:
    Background

    Recent antimicrobial resistance data are lacking from inpatient oncology settings to guide infection prophylaxis and treatment recommendations. We describe central line-associated bloodstream infection (CLABSI) pathogens and antimicrobial resistance patterns reported from oncology locations to the CDC’s National Healthcare Safety Network (NHSN).

    Methods

    CLABSI data reported to NHSN from 2009–2012 from adult inpatient oncology locations were compared to data from non-oncology adult locations within the same hospitals. Pathogen profile, antimicrobial resistance rates, and CLABSI incidence rates/per 1000 central line-days were calculated. CLABSI incidence rates were compared using Poisson regression.

    Results

    During 2009–2012, 4654 CLABSIs were reported to NHSN from 299 adult oncology units. The most common organisms causing CLABSI in oncology locations were coagulase-negative staphylococci (16.9%), Escherichia coli (11.8%), and Enterococcus faecium (11.4%). Fluoroquinolone resistance was more common among E. coli CLABSI in oncology than non-oncology locations (56.5% vs 41.5% of isolates tested, P<0.0001) and increased significantly from 2009–2010 to 2011–2012 (49.5% vs 60.4%, P=0.01). Furthermore, rates of CLABSI were significantly higher in oncology compared to non-oncology locations for fluoroquinolone-resistant E. coli (rate ratio: 7.37, 95% confidence interval, 6.20–8.76) and vancomycin-resistant E. faecium (rate ratio: 2.27, 95% confidence interval, 2.03–2.53). However, resistance rates for some organisms, such as Klebsiella spp. and Pseudomonas aeruginosa, were lower in oncology than in non-oncology locations.

    Conclusions

    Antimicrobial-resistant E. coli and E. faecium have become significant pathogens in oncology. Practices for antimicrobial prophylaxis and empiric antimicrobial therapy should be regularly assessed in conjunction with contemporary antimicrobial resistance data.

  • Subjects:
  • Source:
    Clin Infect Dis. 62(10):1203-1209
  • Pubmed ID:
    26936664
  • Pubmed Central ID:
    PMC4894695
  • Document Type:
    Journal Article
  • Funding:
    CC999999/Intramural CDC HHSUnited States/
  • Collection(s):
  • Main Document Checksum:
  • Download URL:
  • File Type:

You May Also Like

Checkout today's featured content at stacks.cdc.gov